Mehtsun WT, McCleary NJ, Maduekwe UN, et al. - Researchers examined whether adjuvant chemotherapy (AC) following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma (PDAC) is associated with additional benefit among patients 80 years and older.

• A cohort study of 2,569 patients 80 years and older diagnosed with PDAC (stage I-III) between 2004 to 2016 who underwent a pancreaticoduodenectomy.

• Adjuvant chemotherapy was received by 47.4% of the patients.

• The adjuvant chemotherapy group had significantly longer median overall survival across the overall cohort, the propensity-matched cohort, and all subgroups.

• Overall findings support further exploration of adjuvant treatment paradigms for patients 80 years and older with PDAC, as a group of patients appeared to be benefitted from curative intent with surgery and chemotherapy.